Genmab A/S (CPH:GMAB)
1,819.00
-21.50 (-1.17%)
Sep 29, 2025, 4:01 PM CET
Genmab Revenue
Genmab had revenue of $925.00M USD in the quarter ending June 30, 2025, with 18.74% growth. This brings the company's revenue in the last twelve months to $3.65B, up 32.97% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.65B
Revenue Growth
+32.97%
P/S Ratio
4.89
Revenue / Employee
$1.36M
Employees
2,682
Market Cap
113.29B DKK
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Novo Nordisk | 311.94B |
Coloplast | 27.87B |
Demant | 22.59B |
ALK-Abelló | 5.86B |
H. Lundbeck | 23.52B |
Zealand Pharma | 9.11B |
Ambu A/S | 5.96B |
Bavarian Nordic | 6.46B |
Genmab News
- 2 hours ago - This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired. - Barrons
- 6 hours ago - Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline - Invezz
- 8 hours ago - Genmab to buy Dutch cancer drugmaker Merus for $8 billion - Reuters
- 8 hours ago - Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - Business Wire
- 8 hours ago - Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - GlobeNewsWire
- 3 days ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire
- 4 days ago - Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 days ago - GMAB: Guggenheim Upgrades Genmab's Rating to 'Buy' on September 24, 2025 | GMAB Stock News - GuruFocus